In the present clinical study, however, the prescription of ARBs, i.e. AT1 receptor antagonists, had significant impact on DPN development that was equal to or greater than ACEIs in T2DM patients (see Figs. 2 and 3), suggesting the essential role of the Ang II/AT1 receptor system in DPN development. The gene discussed is AGTR1; the disease is type 2 diabetes mellitus.